WO2021076506A1 - A stable effervescent co-processed excipient composition and a process for preparing the same - Google Patents

A stable effervescent co-processed excipient composition and a process for preparing the same Download PDF

Info

Publication number
WO2021076506A1
WO2021076506A1 PCT/US2020/055400 US2020055400W WO2021076506A1 WO 2021076506 A1 WO2021076506 A1 WO 2021076506A1 US 2020055400 W US2020055400 W US 2020055400W WO 2021076506 A1 WO2021076506 A1 WO 2021076506A1
Authority
WO
WIPO (PCT)
Prior art keywords
effervescent
carbonate
processed
group
stable
Prior art date
Application number
PCT/US2020/055400
Other languages
French (fr)
Inventor
Mahesh Desai
Robert Mccrimlisk
Quyen Vo SCHWING
Original Assignee
Isp Investments Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isp Investments Llc filed Critical Isp Investments Llc
Priority to KR1020227015796A priority Critical patent/KR20220084089A/en
Priority to BR112022007397A priority patent/BR112022007397A2/en
Priority to CN202080081539.8A priority patent/CN114727952A/en
Priority to US17/769,679 priority patent/US20220362141A1/en
Priority to CA3154949A priority patent/CA3154949C/en
Priority to JP2022522995A priority patent/JP2022553004A/en
Priority to MX2022004643A priority patent/MX2022004643A/en
Priority to EP20875837.5A priority patent/EP4045008A4/en
Publication of WO2021076506A1 publication Critical patent/WO2021076506A1/en
Priority to IL292304A priority patent/IL292304A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/40—Effervescence-generating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • the present application relates to a dry stable effervescent co-processed excipient composition
  • a dry stable effervescent co-processed excipient composition comprising: (!) about 0.1 to about 50 wt.% of one or more carbonate bases; (ii) about 0.1 to about 50 wt.% of a water soluble carbohydrate sugar alcohol and; (id) about 0.001 to about 40 wt.% of one or more organic acids.
  • the composition is shelf stable in standard, product packaging and useful in standard ready to mix beverages.
  • Effervescent dosage forms are well known and accepted as patient and consumer centric oral delivery systems for nutritional supplements and medicines.
  • a carbonate base such as sodi um or potassium bicarbonate
  • a suitable organic acid such as citric, malic or tartaric acid
  • the acid and base react vigorously to release CO 2 in the form of bubbles or fizzing which is generally associated with an enhanced sensory experi ence by the consumer.
  • Such dosage forms can be formulated into granules which are packaged into sachets and dispersed in a glass of water at the time of use or compressed into effervescent tablets which can be dissolved into a glass of water resulting in an appealing carbonated beverage.
  • the effervescent reaction can also be triggered by environmental moisture, i.e., humidity present in the air.
  • environmental moisture i.e., humidity present in the air.
  • HVAC Heating Ventilation and Air Conditioning
  • the finished dosage forms need to be packaged in suitable moisture resistant packaging such as multilayered resistant laminated foil sachets or aluminum tubes and desiccants to hold the tablets,
  • suitable moisture resistant packaging such as multilayered resistant laminated foil sachets or aluminum tubes and desiccants to hold the tablets
  • R.H relative humidity
  • US5709886A describes a process for microencapsulating a finely divided admixture of sodium bicarbonate and citric acid to produce a taste masked effervescent material comprising individual microcapsnles each containing an effervescent, mixture of sodium bicarbonate and citric acid encapsulated with ethy!celhilose.
  • the process comprises forming a granulate admixture of sodium bicarbonate and citric acid, and charging the admixture of sodium bicarbonate and citric acid to a coacervating medium that includes cyclohexane as a solvent, ethyleellulose as an encapsulating polymer, and a phase inducing polymer, and separating the microcapsules,
  • WO 1995023594A1 describes a granular product or tablet containing an effervescent system and an active pharmaceutical substance and a method for its preparation.
  • sodium bicarbonate and potassium bicarbonate can be granulated with mannitol, which is a water soluble carbohydrate sugar alcohol and blended with citric acid co-processed with water-soluble mannitol to yield a co-processed excipient composition which is stable in atmospheric ambient conditions under open dish conditions and in simple polyethylene bags at 40 °C and 75% relative humidity for extended periods of time.
  • mannitol which is a water soluble carbohydrate sugar alcohol
  • citric acid co-processed with water-soluble mannitol to yield a co-processed excipient composition which is stable in atmospheric ambient conditions under open dish conditions and in simple polyethylene bags at 40 °C and 75% relative humidity for extended periods of time.
  • the present application discloses a dry stable effervescent granulation that is stable even after two months and is free of any caking or clumping which is a problematic indicator in effervescent blends.
  • An objective of the present application is to provide a dry stable effervescent co- processed excipient composition
  • a dry stable effervescent co- processed excipient composition comprising: (i) about 0.1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and mixtures thereof; f ii) about 0.1 to about 50 wt.% of one or more water soluble carbohydrate sugar' alcohols selected from the group consisting of mannitol, maltitol, lactitol xylitol, erythritol and mixtures thereof and; (iii) about 0.00.1 to about 40 wt.% of one or more organic acids.
  • an effervescent co-processed excipient composition used for (i) enhancing stability of the composition (it) developing free flowing and highly cempaetible compositions and, (iii) developing effervescent formulations that are shelf stable in a standard product packaging.
  • the compositions and form ulations can be used in standard ready to mix beverages.
  • Another aspect of the present application discloses a process for preparing a co- processed finely divided : admixture comprising individual particle of an effervescent carbonate base or mixture of carbonate bases encapsulated with mannitol, wherein the process comprises admixing co-processed base or bases with mannitol in. solution at 20 to 30% solids and spraying onto the surface of the base or base-mix in an amount sufficient to achieve about an 8:2 weight ratio gain to provide a barrier to prevent premature reaction, drying the resultant encapsulate and dry blending with citric acid co-processed with mannitol
  • an oral solid dosage form in the form of tablets, capsules, pellets, granules or a sachet comprising: (i) about 0.1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of sodium bicarbonate (NaHCO 3 ), potassium bicarbonate (KHCO 3 ), sodium carbonate (Na 2 CO 3 ), potassium carbonate (K 2 CO 3 ) and combinations thereof: (ii) about 0.1 to about 50 wt.% of mannitol; (iii) about 0.001 to about 40 wt.% of one or more organic acids; (iv) about I to about 3 wt.% of one or more sweeteners selected fiom the group consisting of stevia, aspartame, sucralose and saccharin; and (v) about 0.1 to about 1 wt.% of one or more food grade oils or flavors selected from the group consisting of avocado, coconut, palm, olive,
  • Figure 1 shows very uniform particle stee distribution of the Stable effervescent co- processed excipient measured by using Malvern Mastersizer 3000 at the laser power of 71 ,35% with the beam length of 10mm.
  • Figure 2 represents powder flow measured by the flow function parameter using a Brookfield powder flow tester. A larger How function indicates better flow.
  • Figure 3 shows the moisture sorption isotherm for the stable effervescent co- processed excipient obtained using TGA Q5000 instrument with the method log as follows: humidity increases from 0% to 70% at 25 °C.
  • Figure 4 shows that stable effervescent eo-proeessed excipient is stable at ambient conditions stored in an open dish for 5 days and remains stable packaged in a simple
  • Figure 5 represents tablet hardness of each electrolyte effervescent tablet formulation tested using Natoli automated tablet hardness tester.
  • Figure 6 shows cherry extract effervescent tablets have similar tablet hardness of 18 kp and disintegration time of 120 seconds, confirming effervescent tablet formulations with stable effervescent co-processed excipient are very stable and short disintegration time.
  • Figure 7 shows morphology of stable effervescent granulation are well coated particle with moisture protective barrier using Scanning Electron Microscopy (SEM).
  • Figure 8 shows pH of stability sampl es have minimal change in pH, indicating stable effervescent granulation maintained its chemical properties using the USP 791 method.
  • Figure 9 shows water activity of packaged stability samples, the 40 °C/75% RH samples had the highest water activity, indicating the stable effervescent granulation is most stable at room, temperature (warehouse) or 25 °C/60%. RH conditions using the USP 922 water acti vity method.
  • Figure 10 shows tablet characterization of the tablets with the stable effervescent granulation maintain hardness and disintegration time.
  • the designated value may vary by plus or minus twelve percent, or eleven percent, or ten percent, or nine percent, or eight percent, or seven percent, or six percent, or five percent, or four percent, or three percent, or two percent, or one percent.
  • the use of fee term “at least one” will be understood to include one as well as any quantity more than one. Including but not limited to, 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc.
  • the term “at least one” or “at least two” may extend up to 100 or 1000 or more depending on the term to which it is attached.
  • A, B, C, or combinations thereof’ is intended to include at least one of: A, B, C, AB, AC, B €, or ABC and, if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB.
  • expressly included are combinations that contain repeats of one or more items or terras, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth.
  • BB Biller Identifier
  • AAA AAA
  • AAB AAA
  • BBC AAABCCCCCC
  • CBBAAA CABABB
  • a dry stable effervescent co-processed excipient composition comprising: (i) about 0,1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and .mixtures thereof; (ii) about 0.1 to about 50 wi.% of one or more sugar alcohol selected from the group consisting of mannitol, mahitol, lactitol, xylitol erythritol and mixtures thereof; and (in) about 0.001 to about 40 wt.% of one or more organic adds.
  • the carbonate base is selected from the group consisti ng of alkali carbonate, alkali bicarbonate, alkal ine earth carbonate, alkaline earth bicarbonate and mixtures thereof
  • the one or more carbonate bases can be selected from the group consisting of sodium bicarbonate (NaHCOs), potassium bicarbonate (KHCOs), sodium carbonate (Na2CO.fi, potassium carbonate (K2CO3) and combinations thereof
  • the carbonate base is present in suitable amounts ranging from about 0.1 wt.% to about 1 wt.%, or from about I wt.% to about 5 wt.%, or from about 5 wt.% to about 10 wt.% or from about 10 wt. % to about 20 wt. %, or from about 20 wt.% to about 30 wt.%, or from about 30 wt.% to about 40 wt.%, or from about 40 wt.% to about 50 wt.% based on the total weight of the composition of the present application.
  • the water-soluble carbohydrate sugar alcohol is selected from the group consisting of mannitol, maititol, lactitol, xylitol, erythritol and combinations thereof.
  • the water-soluble carbohydrate sugar alcohol is mannitol
  • the water-soluble carbohydrate sugar alcohol is mannitol present in suitable amounts ranging from about 0.1 wt.% to about 1 wt.%, or from about .1 wt.% to about 5 wt.%, or from about 5 wt.% to about 10 wt.% or from about 10 wt. % to about 20 wt. %, or from about 20 wt.% to about 30 wt.%, or from about 30 wt.% to about 40 wt.%, or from about 40 wt.% to about 50 wt.% based on the total weight of the composition of the present application.
  • the organic acid is edible and selected from the group consisting of citric acid, malic acid and tartaric acid.
  • the organic acids is/are present in suitable amounts ranging from about 0.001 wt.% to about 0.01 wt.%, from about 0.01 wt.% to about 0.1 wt.%, or from about 0.1 wt.% to about 1 wt.%, from about 0.1 wt.% to about 1 wt.%, or from about, 1 wt.% to about 5 wt.%, or from about 5 wt.% to about 10 wt.% or from about 10 wt, % to about 20 wt. %, or from about 20 wt.% to about 30 wt.%, or from about 30 wt.% to about.40 wt.% based on the total weight of the composition of the present application.
  • the composition of the present application comprises one or more sweetening agents selected from the group including, but not limited to, stevia, sucrose, glucose, saccharin, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, dihydrochalcones, acesulfame, sucralose, cyclamate salts, sodium cyclamate, sodium saccharin, and mixtures thereof
  • the composition contains from about 1 wt.% to about 3 wt.% of one or more sweetening agents by weight of the total composition,
  • the composition of the present application comprises one or more sweetening agents selected from the group including, but not limited to, stevia, sucrose, glucose, saccharin, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, dihydrochalcones, acesulfame, sucralose, cyclamate salts, sodium cyclamate, sodium saccharin, and mixtures thereof.
  • the composition contains from about 0.1 wt.% to about 1 wt.%, of one or more sweetening agents by weight of the total composition.
  • the composition of the present application comprises lubricants and flavoring oils selected from the group including, but not limited to, avocado oil, coconut oil, paint oil, olive oil, corn oil, sunflower oil, almond oil, canola oil, anise oil, clove oil, sassafras oil, spearmint oil, peppermint oil, oil of wintergreen and mixtures thereof.
  • the composition contains from about 1 wt. % to about 3 wt, % of lubricants and flavoring agents.
  • the composition contains from about 0.1 wt. % to about 1 wt. % of one or more food grade oils or flavors by weight of the total composition.
  • Another embodiment of the present application discloses an effervescent co-excipient composition used for (i) enhancing stability of the composition, (ii> developing free flowing and highly compactible compositions and, (iii) developing effervescent formulations that are shelf stable in standard product packaging.
  • the composion can be used in a standard ready to mix beverages.
  • Yet another embodiment of the present application discloses a process for co- processing a finely divided admixture comprising individual particle of an effervescent carbonate base or mixture of carbonate bases encapsulated with mannitol or any other water soluble carbohydrate sugar alcohol, wherein the process comprises admixing co-processed base or bases with the mannitol or other water soluble carbohydrate sugar alcohol in solution at 20 to 30% solids and spraying onto the surface of the base or base-mix in an amount sufficient to achieve about an 8:2 weight ratio gain to provide a barrier to prevent premature reaction, drying the resultant encapsulate and dry blending with citric acid co-processed with mannitol,
  • the effervescent co-processed excipient composition can be used in pharmaceutical, food, industrial, biocide, preservative, nutraceutical or agrochemical formulations or compositions.
  • the effervescent co-processed excipient composition can he used in pharmaceutical, food and nutracenticai formulations or compositions.
  • a different embodiment of the present application discloses an oral solid dosage form comprising: (a) a dry stable effervescent co-processed excipient composition comprising: (i) about 0.1 to about 50 wt% of one or more carbonate bases selected from the group consisting of sodium bicarbonate (NaHCO3), potassium bicarbonate ( KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) and combinations thereof; (it) 0.001.
  • a dry stable effervescent co-processed excipient composition comprising: (i) about 0.1 to about 50 wt% of one or more carbonate bases selected from the group consisting of sodium bicarbonate (NaHCO3), potassium bicarbonate ( KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) and combinations thereof; (it) 0.001.
  • the oral solid dosage form is present in suitable amounts ranging from about 10 wt.% to about 20 wt.%, or from about 20 wt,% to about 30 wt.%, or from about 30 wt.% to about 40 wt.%, from about 40 wt.% to about 50 wt.%, or from about 50 wt.% to about 60 wt.%, or from about 60 wt.% to about 70 wt.% or from about 70 wt % to about 75 wt.% and comprises a dry stable effervescent mo-processed excipient composition comprising ; (i) about 0.1 to about 50 wt.% of one or more carbonate bases selected from.
  • NaHCO3 sodium bicarbonate
  • KHCO3 potassium bicarbonate
  • Na2CO3 sodium carbonate
  • K2CO3 potassium carbonate
  • the oral solid dosage form is in the form of tablets, capsules, pellets, mini tablets, grannies or a sachet.
  • the present application discloses that the oral solid dosage Includes a food, a pharmaceutical, or a nuiraceutkal ingredient.
  • the composition of the present application preferably in oral solid dosage form comprises a flavoring agent which can include, but is not limited to, avocado oil, anise oil, clove oil, sassafras oil, spearmint oil, berry flavor and mixtures thereof.
  • a flavoring agent which can include, but is not limited to, avocado oil, anise oil, clove oil, sassafras oil, spearmint oil, berry flavor and mixtures thereof.
  • the composition preferably contains such flavoring agent in an amount from about 0.1% to about 1%, by weight of the composition.
  • Example 1 Manufacturing procedure for part. A co-processed carbonate base
  • composition of the stable effervescent co-processed excipient granulation was based on the Stoichiometric ratios of bicarbonate, carbonate and citric as per the reactions below;
  • Example 2 Water Activity after 5 days of stable effervescent co-processed excipient
  • Tablet characterization at compression force of 50kN and tablets with effervescent granulation maintain hardness and compression strength (Table 6a) and use level of tablets (Table 6b and Table 6c) given in Figure 10.
  • Table 6a Electrolyte replacement effervescent tablet
  • Tablet hardness for the electrolyte replacement effervescent tablets were tested using Natoli automated tablet hardness tester. The disintegration time of each tablet was also measured in deionized water at 37 °C (Table 7).
  • Example 5 Stable effervescent co-processed excipient powder
  • Particle size distribution of the stable effervescent co-processed excipient was measured using Malvern Mastersizer 3000 at (470nm) laser power of 71.35% and beam length of 10.0 nm.
  • Figure 1 shows stable effervescent co-proeessed excipient has a very uniform particle size distribution.
  • Stable effervescent co-processed excipient powder flowabilty was measured using Brookfield Engineering Lab Instrument maximum stress 13.252 kPa with axial speed 1.0 mm/sec and rotational speed 1.0 rev/ hr.
  • Stable effervescent co-processed excipient has excellent powder flow for low variability during direct compression tableting process (Figure 2).
  • Vapor absorption of the stable effervescent co-processed excipient was measured at different humidity condition using TGA Q5000 Instrument with the method log: Equilibrate at 60.00 °C: Humidity 0.00 %: Abort next iso if Weight(%) ⁇ 0.0100 for 15.00 min; Isothermal for 1440.00 min; Mark data; Equilibrate at 25.00°C; Humidity 10.00 %; Abort next iso if Weight(% ⁇ ⁇ 0.01.00 for 15.00 min; Isothermal for 1440.00 min; Mark data; Abort next iso if Weight(%) ⁇ 0.0100 for 15.00 min; Step humidity 10.00 % every 1440.00 min to 90.00 %.
  • Stable effervescent co-processed excipient has low moisture uptake in humid environments (less than 0.3% at 60% RE) (Figure 3).
  • electrolyte replacement blend and tart cherry extract effervescent tablet formulations with stable effervescent co-processed effervescent excipient show similar tablethardness and disintegration time at different stability conditions.
  • the disintegration time of each tablet was measured in deionized water at 37 °C. All tablet formulations have tablet hardness around 14 kp and disintegration time of 120 - 150 seconds, indicating electrolyte tablet formulations with different stable effervescent co-processed excipient samples which were exposed at different stress conditions have good tablet formulation stability (Figure 5 and Figure 6).
  • the sample was mounted on a sample stub, coated with a thin layer of Au/Pd to make the sample surface conductive and then examined in SEI (Secondary Electron imaging) mode.
  • SEI Secondary Electron imaging
  • SEI records the topographical features of the sample surface. Representati ve photomicrographs were digitally captured at 2048x1594 pixel resolution. The samples were examined at multiple magnifications and areas. The image was presented in the Figure 7.

Abstract

A dry stable effervescent co-processed excipient composition comprising; (i) about 0,1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and mixtures thereof; (ii) about 0.1 to about 50 wt.% of a water soluble carbohydrate sugar alcohol and; (iii) about 0.001 to about 40 wt.% of one or more organic acids. Also disclosed is a process for preparing the composition.

Description

A STABLE EFFERVESCENT CO-PROCESSED EXCIPIENT COMPOSITION AND
A PROCESS FOR PREPARING THE SAME
FIELD OF THE INVENTION
[0001] The present application relates to a dry stable effervescent co-processed excipient composition comprising: (!) about 0.1 to about 50 wt.% of one or more carbonate bases; (ii) about 0.1 to about 50 wt.% of a water soluble carbohydrate sugar alcohol and; (id) about 0.001 to about 40 wt.% of one or more organic acids. The composition is shelf stable in standard, product packaging and useful in standard ready to mix beverages.
BACKGROUND OF THE INVENTION
[0002] Effervescent dosage forms are well known and accepted as patient and consumer centric oral delivery systems for nutritional supplements and medicines. To achieve effervescence, the appropriate stoichiometric proportions of a carbonate base such as sodi um or potassium bicarbonate and a suitable organic acid such as citric, malic or tartaric acid is combined in foe presence of water. The acid and base react vigorously to release CO2 in the form of bubbles or fizzing which is generally associated with an enhanced sensory experi ence by the consumer. Such dosage forms can be formulated into granules which are packaged into sachets and dispersed in a glass of water at the time of use or compressed into effervescent tablets which can be dissolved into a glass of water resulting in an appealing carbonated beverage.
[0003] Current effervescent products require extreme low humidity processing and packaging environments for commercial products. Expensive equipment and packaging components are required with high rates of failure due to early unwanted reaction of the formulations.
[0004] While such dosage forms are desired and convenient, the effervescent reaction can also be triggered by environmental moisture, i.e., humidity present in the air. This makes manufacturing effervescent dosage forms highly specialized and costly as plants need to be equipped with suitable Heating Ventilation and Air Conditioning (HVAC) equipment that can maintain relative humidity below 30%, and ideally below 25%, year-round. Additionally, the finished dosage forms need to be packaged in suitable moisture resistant packaging such as multilayered resistant laminated foil sachets or aluminum tubes and desiccants to hold the tablets, A need therefore exists for a ready to use stabilized co-processed excipient composition that has effervescent properties and can be used to make dosage forms that do not require special packaging and, furthermore, can be handled in manufacturing plants with conventional HVAC systems which maintain relative humidity (R.H) between 30-55% depending on season and weather conditions rather than specialized humidity controlling HV AC systems.
[0005] US5709886A describes a process for microencapsulating a finely divided admixture of sodium bicarbonate and citric acid to produce a taste masked effervescent material comprising individual microcapsnles each containing an effervescent, mixture of sodium bicarbonate and citric acid encapsulated with ethy!celhilose. The process comprises forming a granulate admixture of sodium bicarbonate and citric acid, and charging the admixture of sodium bicarbonate and citric acid to a coacervating medium that includes cyclohexane as a solvent, ethyleellulose as an encapsulating polymer, and a phase inducing polymer, and separating the microcapsules,
[ 0006 ] WO 1995023594A1 describes a granular product or tablet containing an effervescent system and an active pharmaceutical substance and a method for its preparation.
[0007] We have unexpectedly found that sodium bicarbonate and potassium bicarbonate can be granulated with mannitol, which is a water soluble carbohydrate sugar alcohol and blended with citric acid co-processed with water-soluble mannitol to yield a co-processed excipient composition which is stable in atmospheric ambient conditions under open dish conditions and in simple polyethylene bags at 40 °C and 75% relative humidity for extended periods of time.
[0008] The present application discloses a dry stable effervescent granulation that is stable even after two months and is free of any caking or clumping which is a problematic indicator in effervescent blends.
SUMMARY OF THE INVENTION
[0009] An objective of the present application is to provide a dry stable effervescent co- processed excipient composition comprising: (i) about 0.1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and mixtures thereof; f ii) about 0.1 to about 50 wt.% of one or more water soluble carbohydrate sugar' alcohols selected from the group consisting of mannitol, maltitol, lactitol xylitol, erythritol and mixtures thereof and; (iii) about 0.00.1 to about 40 wt.% of one or more organic acids.
[0010] According to one aspect, of the present application, there is provided an effervescent co-processed excipient composition used for (i) enhancing stability of the composition (it) developing free flowing and highly cempaetible compositions and, (iii) developing effervescent formulations that are shelf stable in a standard product packaging. The compositions and form ulations can be used in standard ready to mix beverages.
[00 P I Another aspect of the present application discloses a process for preparing a co- processed finely divided: admixture comprising individual particle of an effervescent carbonate base or mixture of carbonate bases encapsulated with mannitol, wherein the process comprises admixing co-processed base or bases with mannitol in. solution at 20 to 30% solids and spraying onto the surface of the base or base-mix in an amount sufficient to achieve about an 8:2 weight ratio gain to provide a barrier to prevent premature reaction, drying the resultant encapsulate and dry blending with citric acid co-processed with mannitol
[ 0012 ] Yet another aspect of the present application provides an oral solid dosage form in the form of tablets, capsules, pellets, granules or a sachet comprising: (i) about 0.1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) and combinations thereof: (ii) about 0.1 to about 50 wt.% of mannitol; (iii) about 0.001 to about 40 wt.% of one or more organic acids; (iv) about I to about 3 wt.% of one or more sweeteners selected fiom the group consisting of stevia, aspartame, sucralose and saccharin; and (v) about 0.1 to about 1 wt.% of one or more food grade oils or flavors selected from the group consisting of avocado, coconut, palm, olive, com, sunflower, almond, canola, berry, cherry, passion fruit, orange, blue ice, tropical fruit, raspberry, lemon and mixtures thereof. BRIEF DESCRIPTION OF THE FIGURES
[0013] Further embodiments of the present application can he understood with reference to the appended figures.
[0014] Figure 1 shows very uniform particle stee distribution of the Stable effervescent co- processed excipient measured by using Malvern Mastersizer 3000 at the laser power of 71 ,35% with the beam length of 10mm.
[0015] Figure 2 represents powder flow measured by the flow function parameter using a Brookfield powder flow tester. A larger How function indicates better flow.
[0016] Figure 3 shows the moisture sorption isotherm for the stable effervescent co- processed excipient obtained using TGA Q5000 instrument with the method log as follows: humidity increases from 0% to 70% at 25 °C.
[0017] Figure 4 shows that stable effervescent eo-proeessed excipient is stable at ambient conditions stored in an open dish for 5 days and remains stable packaged in a simple
Polyethylene bags when stored at 25 °C, 60% RH and 40 °C, 75% RH for 5 days.
[0018] Figure 5 represents tablet hardness of each electrolyte effervescent tablet formulation tested using Natoli automated tablet hardness tester.
[0019] Figure 6 shows cherry extract effervescent tablets have similar tablet hardness of 18 kp and disintegration time of 120 seconds, confirming effervescent tablet formulations with stable effervescent co-processed excipient are very stable and short disintegration time.
[0020] Figure 7 shows morphology of stable effervescent granulation are well coated particle with moisture protective barrier using Scanning Electron Microscopy (SEM).
[0021] Figure 8 shows pH of stability sampl es have minimal change in pH, indicating stable effervescent granulation maintained its chemical properties using the USP 791 method.
[0022] Figure 9 shows water activity of packaged stability samples, the 40 °C/75% RH samples had the highest water activity, indicating the stable effervescent granulation is most stable at room, temperature (warehouse) or 25 °C/60%. RH conditions using the USP 922 water acti vity method.
[0023 ] Figure 10 shows tablet characterization of the tablets with the stable effervescent granulation maintain hardness and disintegration time. DETAILED DESCRIPTION OF THE INTENTION
[0024] Before explaining at least one embodiment of the present disclosure in detail, it is to be understood that the present disclosure is not limited in. its application to the details of construction and the arrangement of the components or steps or methodol ogies set fort h in the following description or illustrated in the drawings. The present disclosure is capable of other embodiments or of being practiced or carried out in many ways. Also, il is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting,
[0025] Unless otherwise defined herein, technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0026] All patents, published patent applications, and non-patent publications mentioned in the specification are indicative of the level of skill of those skilled in the art to which the present disclosure pertains. Ail patents, published patent applications, and non-patent publications referenced in any portion of this application are herein expressly incorporated by reference in their entirety to the same extent as if each individual patent or publication was specifically and individually indicated to be incorporated by reference.
[0027] All of the articles and/or methods disclosed herein can he made and executed without undue experimentation in light of the present disclosure. While the articles and methods of the present disclos ure have been described in terms of preferred embodimen ts, it will be apparent to those of ordinary skill in the art that variations may be applied to the articles and/or methods and in the steps or is the sequence of steps of the method(s) described herein without departing from the concept, spirit and scope of the present disclosure. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit scope and concept of the present disclosure.
[0028] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall he understood to have the following meanings.
[0029] The use of the word “a” or “an” when used in conjunction with the term “comprising” may mean “one.” but it is also consistent with the meaning of rime or more,” “at least one,” and “one or more than one,” lire use of the term “or” is used to mean “and/or” unless explicitly indicated to refer to alternatives only if fee alternatives are mutually exclusive, although fee disclosure supports a definition that refers to only alternatives and. “and/or.” Throughout this application, fee term “about” is used to indicate feat a value includes fee inherent variation of error for the quantifying device, fee mefeod(s) being employed to determine fee value, or the variation that exists among fee study subjects. For example, but not by way of limitation, when the term “about” is utilized, the designated value may vary by plus or minus twelve percent, or eleven percent, or ten percent, or nine percent, or eight percent, or seven percent, or six percent, or five percent, or four percent, or three percent, or two percent, or one percent. The use of fee term “at least one” will be understood to include one as well as any quantity more than one. Including but not limited to, 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term “at least one” or “at least two” may extend up to 100 or 1000 or more depending on the term to which it is attached. In addition, the quantities of 100/1000 are not to be considered bruiting as lower or higher limits may also produce satisfactory results, in addition, fee use of the term “at least one of X, Y, and Z” will be understood to include X alone, Y alone, and 2 alone, as well as any combination of X, Y, and Z. The use of ordinal number terminology (i.e., “first'’, “second”, “third”, "‘fourth”, etc.) is solely for the purpose of differentiating between two or more items and, unless otherwise stated, is not meant to imply any sequence or order or importance to one item over another or any order of addition.
[0030] As used herein, fee words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “.has”), “i ncluding” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “con tain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. The terms “or combinations thereof’ and: “and/or combinations thereof’ as used herein refer to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof’ is intended to include at least one of: A, B, C, AB, AC, B€, or ABC and, if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing wife this example, expressly included are combinations that contain repeats of one or more items or terras, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwi se apparen t from the context.
[0031] For purposes of the following detailed description, other than in any operating examples, or where otherwise indicated, numbers that express, for example, quantities of ingredients used in the specification and claims are to be understood as being modified in ail instances by the term "about’’. The numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties to be obtained in carrying out the in vention.
[0032] According to one embodiment of the present application, there is provided a dry stable effervescent co-processed excipient composition comprising: (i) about 0,1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and .mixtures thereof; (ii) about 0.1 to about 50 wi.% of one or more sugar alcohol selected from the group consisting of mannitol, mahitol, lactitol, xylitol erythritol and mixtures thereof; and (in) about 0.001 to about 40 wt.% of one or more organic adds.
[0033] in one embodiment of the present application, the carbonate base is selected from the group consisti ng of alkali carbonate, alkali bicarbonate, alkal ine earth carbonate, alkaline earth bicarbonate and mixtures thereof
[0034] In another embodiment of the present application, the one or more carbonate bases can be selected from the group consisting of sodium bicarbonate (NaHCOs), potassium bicarbonate (KHCOs), sodium carbonate (Na2CO.fi, potassium carbonate (K2CO3) and combinations thereof
[0035] In some embodiments, the carbonate base is present in suitable amounts ranging from about 0.1 wt.% to about 1 wt.%, or from about I wt.% to about 5 wt.%, or from about 5 wt.% to about 10 wt.% or from about 10 wt. % to about 20 wt. %, or from about 20 wt.% to about 30 wt.%, or from about 30 wt.% to about 40 wt.%, or from about 40 wt.% to about 50 wt.% based on the total weight of the composition of the present application.
100361 In yet another embodiment of the present application, the water-soluble carbohydrate sugar alcohol is selected from the group consisting of mannitol, maititol, lactitol, xylitol, erythritol and combinations thereof. In a non-limiting embodiment, the water-soluble carbohydrate sugar alcohol is mannitol
[0037] In some embodiments, the water-soluble carbohydrate sugar alcohol is mannitol present in suitable amounts ranging from about 0.1 wt.% to about 1 wt.%, or from about .1 wt.% to about 5 wt.%, or from about 5 wt.% to about 10 wt.% or from about 10 wt. % to about 20 wt. %, or from about 20 wt.% to about 30 wt.%, or from about 30 wt.% to about 40 wt.%, or from about 40 wt.% to about 50 wt.% based on the total weight of the composition of the present application.
[0038] In one embodiment of the present application, the organic acid is edible and selected from the group consisting of citric acid, malic acid and tartaric acid.
[0039] In some embodiments, the organic acids is/are present in suitable amounts ranging from about 0.001 wt.% to about 0.01 wt.%, from about 0.01 wt.% to about 0.1 wt.%, or from about 0.1 wt.% to about 1 wt.%, from about 0.1 wt.% to about 1 wt.%, or from about, 1 wt.% to about 5 wt.%, or from about 5 wt.% to about 10 wt.% or from about 10 wt, % to about 20 wt. %, or from about 20 wt.% to about 30 wt.%, or from about 30 wt.% to about.40 wt.% based on the total weight of the composition of the present application.
[0040] in another embodiment, the composition of the present application comprises one or more sweetening agents selected from the group including, but not limited to, stevia, sucrose, glucose, saccharin, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, dihydrochalcones, acesulfame, sucralose, cyclamate salts, sodium cyclamate, sodium saccharin, and mixtures thereof In a non-limiting embodiment, the composition contains from about 1 wt.% to about 3 wt.% of one or more sweetening agents by weight of the total composition,
[0041] In another embodiment, the composition of the present application comprises one or more sweetening agents selected from the group including, but not limited to, stevia, sucrose, glucose, saccharin, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, dihydrochalcones, acesulfame, sucralose, cyclamate salts, sodium cyclamate, sodium saccharin, and mixtures thereof. In a non-limiting embodiment, the composition contains from about 0.1 wt.% to about 1 wt.%, of one or more sweetening agents by weight of the total composition.
[0042] In another embodiment, the composition of the present application comprises lubricants and flavoring oils selected from the group including, but not limited to, avocado oil, coconut oil, paint oil, olive oil, corn oil, sunflower oil, almond oil, canola oil, anise oil, clove oil, sassafras oil, spearmint oil, peppermint oil, oil of wintergreen and mixtures thereof. In a non-limiting embodiment, the composition contains from about 1 wt. % to about 3 wt, % of lubricants and flavoring agents. According to another non-limiting embodiment of the present application, the composition contains from about 0.1 wt. % to about 1 wt. % of one or more food grade oils or flavors by weight of the total composition. [0043] Another embodiment of the present application discloses an effervescent co-excipient composition used for (i) enhancing stability of the composition, (ii> developing free flowing and highly compactible compositions and, (iii) developing effervescent formulations that are shelf stable in standard product packaging. The composion can be used in a standard ready to mix beverages.
[0044] Yet another embodiment of the present application discloses a process for co- processing a finely divided admixture comprising individual particle of an effervescent carbonate base or mixture of carbonate bases encapsulated with mannitol or any other water soluble carbohydrate sugar alcohol, wherein the process comprises admixing co-processed base or bases with the mannitol or other water soluble carbohydrate sugar alcohol in solution at 20 to 30% solids and spraying onto the surface of the base or base-mix in an amount sufficient to achieve about an 8:2 weight ratio gain to provide a barrier to prevent premature reaction, drying the resultant encapsulate and dry blending with citric acid co-processed with mannitol,
[0045] According to another non-limiting embodiment of the present application, the effervescent co-processed excipient composition can be used in pharmaceutical, food, industrial, biocide, preservative, nutraceutical or agrochemical formulations or compositions. In a non-liming embodiment of the present application, the effervescent co-processed excipient composition can he used in pharmaceutical, food and nutracenticai formulations or compositions.
[0046] A different embodiment of the present application discloses an oral solid dosage form comprising: (a) a dry stable effervescent co-processed excipient composition comprising: (i) about 0.1 to about 50 wt% of one or more carbonate bases selected from the group consisting of sodium bicarbonate (NaHCO3), potassium bicarbonate ( KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) and combinations thereof; (it) 0.001. to about 50 wt.% of manni tol; (iii) about 0,001 to about 40 wt.% of one or more organic acids; (b) about 1 to about 3 wt.% of one or more sweeteners selected from the group consisting of stevia, aspartame, sucralose, and saccharin; and (c) about 0.1 to about 1 wt.% of one or more food grade oils or flavors selected from the group consisting of avocado, coconut, palm, olive, corn, sunflower, almond, canola, berry, cherry, passion fruit, orange, blue ice, tropical fruit, raspberry, lemon flavor and mixtures thereof. [0047] In some embodiments, the oral solid dosage form is present in suitable amounts ranging from about 10 wt.% to about 20 wt.%, or from about 20 wt,% to about 30 wt.%, or from about 30 wt.% to about 40 wt.%, from about 40 wt.% to about 50 wt.%, or from about 50 wt.% to about 60 wt.%, or from about 60 wt.% to about 70 wt.% or from about 70 wt % to about 75 wt.% and comprises a dry stable effervescent mo-processed excipient composition comprising ; (i) about 0.1 to about 50 wt.% of one or more carbonate bases selected from. the group consisting of sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) a»d combinations thereof; (ii) 0.001 to about 50 wt.% of mannitol; and (iii) about 0,001 to about 40 wt.% of one or more organic acids.
[0048] According to another embodiment of the present application, the oral solid dosage form is in the form of tablets, capsules, pellets, mini tablets, grannies or a sachet. In some non- limiting embodiments, the present application discloses that the oral solid dosage Includes a food, a pharmaceutical, or a nuiraceutkal ingredient.
[0049] In another embodiment, the composition of the present application preferably in oral solid dosage form comprises a flavoring agent which can include, but is not limited to, avocado oil, anise oil, clove oil, sassafras oil, spearmint oil, berry flavor and mixtures thereof. The composition preferably contains such flavoring agent in an amount from about 0.1% to about 1%, by weight of the composition.
[0050] The following examples are presented for purposes of demonstrating, but not limiting, the preparation and use of the polymers. In the examples, the following abbreviations are used: wt.% or % (w/w) Weight percent kPa Kilopascals kN Kilonewton kP Kilopounds
DI. deionized water
DT disintegration time
RH relative humidity
NaHCO3 sodium bicarbonate
KHCO3 potassium bicarbonate
Na2CO3 sodium carbonate
K2CO3 potassium carbonate
[0051 ] Further, certain aspects of the present application are illustrated in detail by way of the following examples. The examples are given, herein for illustration of the application and are not intended to be limiting thereof. EXAMPLES
Example 1 : Manufacturing procedure for part. A co-processed carbonate base
[0052] Sodium and potassium bicarbonate were combined with potassium carbonate in equal ratios as shown in Table 1 and Table 2 and granulated with mannitol which was added from aqueous solution via top spray granulation in a fluid bed system. Separately, citric acid (Citrocoat-N grade from Jungbunzlauer company) was co-processed in a similar way via top- spray wet granulation with a water dispersed mannitol suspension. After drying and sizing the granulations Tablel and Table 2 are dry blended together to yield the stabilized, co-processed effervescent excipient in a 60,9: to 39,6 ratio (Table 3). The resultant co-processed excipient was stable at ambient conditions stored in tut open dish for 5 days and remains stable packaged in simple PE bags when stored at 25 °C, 60% RH and 40 °C, 75% R.H.
Table I: Composition of co-processed carbonate component
Figure imgf000013_0001
Table 2; Composition of co-processed citric acid component
Figure imgf000013_0002
[0053] Composition of the stable effervescent co-processed excipient granulation was based on the Stoichiometric ratios of bicarbonate, carbonate and citric as per the reactions below;
One H3C6H5O7 (citric acid) + 3 alkali HCO3 = Alkali carbonate salt + 3 CO2 + H2O Two H3C6H5O7 (citric acid) + 3 alkali CD3 = two Alkali carbonate salt + 3 CO2 + 3 H2O [0054] Three motes of alkali bicarbonate require one mote of citric acid and two motes of alkali carbonate requires two moles of citric acid. As a result, the final composition of stable effervescent co-processed excipient granulation contains 50-75% of co-processed carbonate base and 25-40% of co-processed citric base. Table 3 shows one example of stable effervescent co-processed excipient effervescent granulation.
Table 3: Composition of stable effervescent co-processed excipient
Figure imgf000014_0001
Table 4: Stable effervescent co-processed excipient - Formulation
Figure imgf000014_0002
Example 2: Water Activity after 5 days of stable effervescent co-processed excipient and
Uncoated Effervescent Blend
[0055] Several stable effervescent co-processed excipient samples and uncoated effervescent blends were stored at different conditions: at ambient open dish and in a simple polyethylene bag at 25 °C, 60% EH and 40 °C, 75% RH for 5 days.
[0056] Water activity of each uncoated effervescent blend and stable effervescent co- processed excipient samples were measured using an AquaLab instrument which, measures the energy status of the water in the sample (Figure 9). [0057] Table 5 shows proprietary stable effervescent co-processed excipient that has unchanged water activity as uncoated ingredients after 5 days at various challenging storage conditions. That indicates that the stable effervescent excipient can prevent any self- propagation between the acid and carbonate until the time of intended use without being influenced by free surface water.
Table 5: Water Activity after 5 days of stable effervescent co-processed excipient and Uncoated Effervescent Blend
Figure imgf000015_0001
Example 3; Electrolyte replacement tablet formulation
[0058] The stable effervescent co-proeessed excipient was blended with an electrolytereplacement blend and other ingredients (Table 6) to make an effervescent: electrolyte replacement tablet formulation.
Table 6: Electrolyte replacement effervescent tablet formulation
Figure imgf000015_0002
[0059] Tablet characterization at compression force of 50kN and tablets with effervescent granulation maintain hardness and compression strength (Table 6a) and use level of tablets (Table 6b and Table 6c) given in Figure 10. Table 6a: Electrolyte replacement effervescent tablet
Figure imgf000016_0001
Table 6b: Use levels of effervescent drink volume
Figure imgf000016_0002
Table 6c: Use 'Levels of effervescen t tablet
Figure imgf000016_0003
[0060] Tablet hardness for the electrolyte replacement effervescent tablets were tested using Natoli automated tablet hardness tester. The disintegration time of each tablet was also measured in deionized water at 37 °C (Table 7).
Table 7: Tablet characterization at compression force of 50kN
Figure imgf000016_0004
Example 4: Tail cherry extract tablet formulation
[0061] Similar to the electrolyte replacement effervescent tablet .formulations, the stable effervescent co-processed was blended with tart cherry extract, and other ingredients to make a tart cherry extract, effervescent tablet formulation (Table 8).
Table 8: Tart cherry extract tablet formulation
Figure imgf000017_0001
[0062] Tablet hardness of each tart cherry extract effervescent tablet formulation was tested using Natali automated tablet hardness tester. The disintegration time of each tablet was also measured in deionized water at 37°C (Table 9),
Table 9: Tablet characterization at compression force of 50fcN
Figure imgf000017_0002
Example 5: Stable effervescent co-processed excipient powder
[0063] Particle size distribution of the stable effervescent co-processed excipient was measured using Malvern Mastersizer 3000 at (470nm) laser power of 71.35% and beam length of 10.0 nm. Figure 1 shows stable effervescent co-proeessed excipient has a very uniform particle size distribution. Stable effervescent co-processed excipient powder flowabilty was measured using Brookfield Engineering Lab Instrument maximum stress 13.252 kPa with axial speed 1.0 mm/sec and rotational speed 1.0 rev/ hr. [0064] Stable effervescent co-processed excipient has excellent powder flow for low variability during direct compression tableting process (Figure 2). Vapor absorption of the stable effervescent co-processed excipient was measured at different humidity condition using TGA Q5000 Instrument with the method log: Equilibrate at 60.00 °C: Humidity 0.00 %: Abort next iso if Weight(%) < 0.0100 for 15.00 min; Isothermal for 1440.00 min; Mark data; Equilibrate at 25.00°C; Humidity 10.00 %; Abort next iso if Weight(%} < 0.01.00 for 15.00 min; Isothermal for 1440.00 min; Mark data; Abort next iso if Weight(%) < 0.0100 for 15.00 min; Step humidity 10.00 % every 1440.00 min to 90.00 %.
[0065] Stable effervescent co-processed excipient has low moisture uptake in humid environments (less than 0.3% at 60% RE) (Figure 3).
[0066] Stable effervescent co-processed excipient show's visual demonstration of good stability (Figure 4),
[0067] The electrolyte replacement blend and tart cherry extract: effervescent tablet formulations with stable effervescent co-processed effervescent excipient show similar tablethardness and disintegration time at different stability conditions. The disintegration time of each tablet was measured in deionized water at 37 °C. All tablet formulations have tablet hardness around 14 kp and disintegration time of 120 - 150 seconds, indicating electrolyte tablet formulations with different stable effervescent co-processed excipient samples which were exposed at different stress conditions have good tablet formulation stability (Figure 5 and Figure 6).
[0068] The sample was mounted on a sample stub, coated with a thin layer of Au/Pd to make the sample surface conductive and then examined in SEI (Secondary Electron imaging) mode. SEI records the topographical features of the sample surface. Representati ve photomicrographs were digitally captured at 2048x1594 pixel resolution. The samples were examined at multiple magnifications and areas. The image was presented in the Figure 7.
[0069] Using USP 791 method, pH of stability samples show the minimal change in pH, indicating the stable effervescent granulation maintained its chemical properties (Figure 8).
[0070] Using USP 922 water activity method, water activity of packaged stability samples are examined, at the 40 °C/75%RH samples as shown, in Figure 9 had the highest water activity, indicating the stable effervescent granulation was most stable at room temperature (warehouse) or 25°C/60% RH conditions. [0071] While the compositions and methods of the disclosed and/or claimed inventive concepts have been described in terms of particular aspects, it will be apparent to those of ordinary skill in the art that variations may he applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herei n without departing from the concept, spirit and scope of the disclosed and/or claimed inventive concepts. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosed and/or claimed inven ti ve concepts.

Claims

What Is claimed is:
1. A dry stable effeirvesceut co-processed excipient composition comprising: i. about 0.1 to about 50 wt.% of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and mixtures thereof; ii. about 0.1 to about 50 wt.% of one or more water soluble carbohydrate sugar alcoholsselected from the group consisting of mannitol, maltitol, lactitol, xylitol, erythritol and mixtures thereof; and iii. about 0.001 to about 40 wt .% of one or more organic acids.
2. The effervescent co-processed excipient composition according to claim 1, wherein the carbonate base is selected from the group consisting of sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) and combinations thereof.
3. The effervescent co-processed excipient composition according to claim 1, wherein said organic acid is selected from the group consisting of citric acid, malic acid, tartaric acid and mixtures thereof,
4. The effervescent co-processed excipient composition according to claim 1 used for (i) enhancing stability of the composition, (ii) developing a free flowing and highly compatible composition and, (iii) developing an effervescent formulation that is shelf stable in a standard product packaging and standard ready to mix beverages.
5. A process for co-processing a finely divided admixture comprising individual particles of an effervescent carbonate base or mixture of carbonate bases encapsulated with mannitol, wherein the process comprises admixing a co-processed base or bases with mannitol in solution at 20% -30% solids and spraying onto the surface of the base or base-mix in about 8:2 weight ratio gain to provide a barrier to prevent premature reaction, drying the resultant encapsulate and dry blending with citric acid co-processed with mannitol
6. The effervescent co-processed excipient composition of claim 1 used for preparing a tablet, a capsule, a pellet, a mini tablet or a sachet.
7. The effervescent co-processed excipient composition of claim 1 used in pharmaceutical, food, industrial, biocide, preservative, or agrochemical formulations.
8, An oral solid dosage form comprising; a) about 10 to about 75 wt. % of a dry stable effervescent co-processed excipient composition comprising ; (i) about 0,1 to about.50 wt.% of one or more carbonate bases selected from the group consisting of sodium bicarbonate (KaHCO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) and combinations thereof; (ii) 0.001 to about 50 wt.% of mannitol; (iii) about 0,001 to about 40 wt.% of one or more organic acids; b) about 1 to about 3 wt.% of one or more sweeteners selected from the group consisting of stevia, aspartame, sucralose, and saccharin; and c) about 0.1 to about 1 wt.% of one or more food grade oils or flavors selected from the group consisting of avocado, coconut, palm, olive, corn, sunflower, almond, canola, berry, cherry, passion fruit, orange, blue ice, tropical fruit, raspberry, lemon flavor and mixtures thereof
9. The oral solid dosage form according to claim 8, wherein the sweetener is stevia.
10. The oral solid dosage form according to claim 8, wherein the food grade oil or flavor is avocado or berry flavor.
11. The oral solid dosage form according to claim 8, wherein the oral solid dosage form is in the form of a tablet, a capsule, a pellet, a mini tablet, or a granule or a powder.
12. The oral solid dosage form according to claim 8, wherein the oral solid dosage includes a food, a pharmaceutical, or a nutraeeuticai ingredient.
PCT/US2020/055400 2019-10-17 2020-10-13 A stable effervescent co-processed excipient composition and a process for preparing the same WO2021076506A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020227015796A KR20220084089A (en) 2019-10-17 2020-10-13 Stable Effervescent Co-Treatment Excipient Compositions and Methods for Making the Same
BR112022007397A BR112022007397A2 (en) 2019-10-17 2020-10-13 STABLE Effervescent CO-PROCESSED EXCIPIENT COMPOSITION AND PROCESS FOR ITS PREPARATION
CN202080081539.8A CN114727952A (en) 2019-10-17 2020-10-13 Stable effervescent co-processing excipient composition and preparation method thereof
US17/769,679 US20220362141A1 (en) 2019-10-17 2020-10-13 A stable effervescent co-processed excipient composition and a process for preparing the same
CA3154949A CA3154949C (en) 2019-10-17 2020-10-13 A stable effervescent co-processed excipient composition and a process for preparing the same
JP2022522995A JP2022553004A (en) 2019-10-17 2020-10-13 Stable effervescent co-processed excipient compositions and methods for their preparation
MX2022004643A MX2022004643A (en) 2019-10-17 2020-10-13 A stable effervescent co-processed excipient composition and a process for preparing the same.
EP20875837.5A EP4045008A4 (en) 2019-10-17 2020-10-13 A stable effervescent co-processed excipient composition and a process for preparing the same
IL292304A IL292304A (en) 2019-10-17 2022-04-15 A stable effervescent co-processed excipient composition and a process for preparing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916402P 2019-10-17 2019-10-17
US62/916,402 2019-10-17

Publications (1)

Publication Number Publication Date
WO2021076506A1 true WO2021076506A1 (en) 2021-04-22

Family

ID=75538854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/055400 WO2021076506A1 (en) 2019-10-17 2020-10-13 A stable effervescent co-processed excipient composition and a process for preparing the same

Country Status (10)

Country Link
US (1) US20220362141A1 (en)
EP (1) EP4045008A4 (en)
JP (1) JP2022553004A (en)
KR (1) KR20220084089A (en)
CN (1) CN114727952A (en)
BR (1) BR112022007397A2 (en)
CA (1) CA3154949C (en)
IL (1) IL292304A (en)
MX (1) MX2022004643A (en)
WO (1) WO2021076506A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230292992A1 (en) * 2022-03-18 2023-09-21 CapsoVision, Inc. Apparatus for Thermally Stable Capsule Endoscope Using Effervescent Formulation for Controlling Balloon Inflation Rate

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023594A1 (en) * 1994-03-01 1995-09-08 Gerhard Gergely Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
US5709886A (en) * 1995-02-03 1998-01-20 Eurand America, Incorporated Effervescent microcapsules
US20080287456A1 (en) * 2004-05-28 2008-11-20 Imaginot Pty Ltd Oral Therapeutic Compound Delivery System
WO2010059725A1 (en) * 2008-11-18 2010-05-27 One S.R.I. Methods and compositions for weight management and for improving glycemic control
WO2011018501A2 (en) * 2009-08-12 2011-02-17 Laboratoires Expanscience Composition including an unsaponifiable fraction
US20110142968A1 (en) * 2008-06-06 2011-06-16 Tuchinsky David B Nutritional supplement
US8840924B2 (en) * 2005-10-21 2014-09-23 Neos Therapeutics, Lp Compositions and methods of making rapidly dissolving ionically masked formulations
US20150017310A1 (en) * 2012-02-01 2015-01-15 Intercontinental Great Brands Llc Low calorie drink tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217125B (en) * 1993-03-10 1999-11-29 Béres Rt. Sugar- and sodium-free effervescens tablets and granules and process for producing them
CN1651088A (en) * 2004-02-04 2005-08-10 陈建操 Effervescent preparation using alditol as functional ingredient
CN1561952A (en) * 2004-04-15 2005-01-12 上海交通大学 Mitalan gargle effervescence tablet for gargle liquid and its preparing method
CN1778297A (en) * 2004-11-23 2006-05-31 广州威尔曼新药开发中心有限公司 Phentolamine effervescent tablet and its preparation thereof
US9592195B2 (en) * 2010-12-06 2017-03-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
KR101360869B1 (en) * 2011-05-30 2014-02-11 남봉길 Effervescent tablet composition for treating urinary calculus comprising potassium citrate, citric acid and potassium hydrogen carbonate as active ingredients and method for preparing an effervescent tablet using the same
EP2983719A4 (en) * 2013-03-15 2017-01-25 Mylan Inc. Manufacturing process for effervescent dosage forms
EP3505164A1 (en) * 2017-12-31 2019-07-03 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. An effervescent composition comprising erdosteine
CN108157975A (en) * 2018-01-22 2018-06-15 山东天力药业有限公司 A kind of vitamin C effervescent tablet
CN108056474A (en) * 2018-01-22 2018-05-22 山东天力药业有限公司 A kind of multidimensional effervescent tablet and preparation method thereof
CN110292566B (en) * 2019-07-08 2022-03-29 上海中医药大学 Method for reducing sticking quantity of effervescent tablets in actual production

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023594A1 (en) * 1994-03-01 1995-09-08 Gerhard Gergely Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
US5709886A (en) * 1995-02-03 1998-01-20 Eurand America, Incorporated Effervescent microcapsules
US20080287456A1 (en) * 2004-05-28 2008-11-20 Imaginot Pty Ltd Oral Therapeutic Compound Delivery System
US8840924B2 (en) * 2005-10-21 2014-09-23 Neos Therapeutics, Lp Compositions and methods of making rapidly dissolving ionically masked formulations
US20110142968A1 (en) * 2008-06-06 2011-06-16 Tuchinsky David B Nutritional supplement
WO2010059725A1 (en) * 2008-11-18 2010-05-27 One S.R.I. Methods and compositions for weight management and for improving glycemic control
WO2011018501A2 (en) * 2009-08-12 2011-02-17 Laboratoires Expanscience Composition including an unsaponifiable fraction
US20150017310A1 (en) * 2012-02-01 2015-01-15 Intercontinental Great Brands Llc Low calorie drink tablet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4045008A4 *

Also Published As

Publication number Publication date
BR112022007397A2 (en) 2022-09-20
JP2022553004A (en) 2022-12-21
EP4045008A1 (en) 2022-08-24
CN114727952A (en) 2022-07-08
KR20220084089A (en) 2022-06-21
US20220362141A1 (en) 2022-11-17
IL292304A (en) 2022-06-01
MX2022004643A (en) 2022-07-27
CA3154949C (en) 2024-01-16
CA3154949A1 (en) 2021-04-22
EP4045008A4 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
US7118765B2 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US5891476A (en) Tastemasked pharmaceutical system
AU2007261943B2 (en) Reduced coenzyme Q10-containing composition and method for producing the same
US7662799B2 (en) Powder of amino acids and method for producing the same
JP5337027B2 (en) Spherical mannitol crystal particles
PT86414B (en) Process for the preparation of an edulcorating composition encased for use in chewing gum and comestible products
US10105314B2 (en) Orodispersible mannitol
EA004951B1 (en) Process for preparing oral calcium compositions
WO2011151733A2 (en) Fexofenadine-based composition and preparation process therefor
US11166917B2 (en) Direct injection moldable and rapidly disintegrating tablet matrix
US20220362141A1 (en) A stable effervescent co-processed excipient composition and a process for preparing the same
DK2983650T3 (en) ORAL PHARMACEUTICAL COMPOSITION WITH TASTE MASKED NACETYL CYSTEIN
KR20070034797A (en) Acetyl-L-carnitine powders and granules with improved hygroscopicity
KR20070034798A (en) Acetyl-L-carnitine powder or granules with improved hygroscopicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20875837

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3154949

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022522995

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022007397

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227015796

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020875837

Country of ref document: EP

Effective date: 20220517

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112022007397

Country of ref document: BR

Free format text: APRESENTE, NO PRAZO DE 60 (SESSENTA) DIAS, RELATORIO DESCRITIVO E DESENHOS COM O TEXTO TRADUZIDO PARA O PORTUGUES.

ENP Entry into the national phase

Ref document number: 112022007397

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220418